Synta Pharmaceuticals Corp. Stock Nasdaq
Stocks
US87162T2069
Biotechnology & Medical Research
|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| Market Cap | 12.63B 10.86B 10.25B 9.34B 17.45B 1,208B 17.61B 122B 46.98B 612B 47.43B 46.39B 1,945B | P/E 2026 * |
-86.6x | P/E 2027 * | 86.8x |
|---|---|---|---|---|---|
| Enterprise Value | 12.11B 10.41B 9.82B 8.95B 16.73B 1,157B 16.88B 117B 45.02B 587B 45.46B 44.47B 1,865B | EV / Sales 2026 * |
7.93x | EV / Sales 2027 * | 5.45x |
| Free-Float |
94.12% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Synta Pharmaceuticals Corp.
| Manager | Title | Age | Since |
|---|---|---|---|
William Sibold
CEO | Chief Executive Officer | 59 | 08/09/2023 |
Mardi Dier
DFI | Director of Finance/CFO | 62 | 11/03/2024 |
David Soergel
CTO | Chief Tech/Sci/R&D Officer | 58 | 21/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Rebecca Taub
BRD | Director/Board Member | 74 | 01/07/2016 |
Richard Levy
BRD | Director/Board Member | 68 | 11/08/2016 |
James Daly
BRD | Director/Board Member | 64 | 27/06/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.25% | -0.96% | +45.25% | +102.76% | 68.52B | |
| -1.09% | -4.97% | +31.10% | +76.56% | 62.88B | |
| -1.18% | +0.47% | -12.78% | +380.30% | 28.13B | |
| -2.74% | -3.53% | +26.13% | +13.50% | 25.56B | |
| -1.76% | -6.30% | -4.55% | -18.27% | 24.65B | |
| -2.39% | -4.23% | +18.42% | -20.95% | 19.81B | |
| -1.86% | +1.15% | +205.44% | +353.89% | 17.69B | |
| -1.37% | -3.77% | -9.38% | +528.34% | 14.66B | |
| -1.54% | -2.88% | +52.33% | +161.16% | 14.45B | |
| Average | -1.58% | -1.33% | +39.11% | +175.26% | 30.71B | |
| Weighted average by Cap. | -1.28% | -1.41% | +35.72% | +138.83% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.53B 1.31B 1.24B 1.13B 2.11B 146B 2.13B 14.75B 5.68B 74.02B 5.73B 5.61B 235B | 2.14B 1.84B 1.74B 1.59B 2.96B 205B 2.99B 20.73B 7.98B 104B 8.05B 7.88B 330B |
| Net income | -184M -158M -149M -136M -254M -17.58B -256M -1.78B -684M -8.92B -690M -675M -28.32B | 200M 172M 162M 148M 276M 19.12B 279M 1.93B 744M 9.7B 751M 735M 30.81B |
| Net Debt | -525M -451M -426M -388M -725M -50.15B -731M -5.07B -1.95B -25.44B -1.97B -1.93B -80.79B | -943M -811M -765M -697M -1.3B -90.18B -1.32B -9.12B -3.51B -45.74B -3.54B -3.46B -145B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
